However, it provides further insight into the mechanistic role of FCGR polymorphisms in clinical outcomes of cetuximab‐treated, metastatic colorectal cancer, namely, the role of FCGR3A polymorphism in modifying the primary relationship between FCGR2A and clinical outcomes. The gene discussed is FCGR3A; the disease is metastatic colorectal cancer.